Ready to pop, page-29

First 29 Last

Share
Profile

Follow
8horse

26,847 Posts.

1841

07/12/18

20:53

Post #: 36790047
Share

Originally posted by Lyzaqu ↑

Originally posted by 8horse
I’m happy with 67c within next 12 months.clear.png

Is It Too Late To Consider Buying Isentia Group Limited (ASX:ISD)?
Hector Vargas November 26, 2018
Isentia Group Limited (ASX:ISD), which is in the software business, and is based in Australia, received a lot of attention from a substantial price increase on the ASX over the last few months. Less-covered, small caps sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Let’s examine Isentia Group’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

Is Isentia Group still cheap?
Great news for investors – Isentia Group is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is A$0.67, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. Another thing to keep in mind is that Isentia Group’s share price is quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again.

https://simplywall.st/stocks/au/sof...consider-buying-isentia-group-limited-asxisd/
What do you think of simply wall st? It seems to me like many of their articles are generated automatically by bots as semi clickbait...

Expand

Probably it's alright as it was written by an analyst, not like many other computerised technical analysis. But it didn't provide much fundamental analysis.

The official ASX announcements and company news should provide a much more clear picture of the fundamentals.

ISD Price at posting: 31.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

ME1

Banshee's historic trenches prove rich in antimony and gold for GDM

AN1

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

AUN

Cyclone signs MOU with Vale for development of Iron Bear play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EDE

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

LYN

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

There are more pages in this discussion • 279 more messages in this thread...

First 29 Last

Add ISD (ASX) to my watchlist

Ready to pop, page-29

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain